ImmunityBio, Inc. (IBRX)
| Market Cap | 8.69B +226.9% |
| Revenue (ttm) | 113.29M +668.3% |
| Net Income | -351.40M |
| EPS | -0.38 |
| Shares Out | 1.03B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,645,348 |
| Open | 8.29 |
| Previous Close | 8.67 |
| Day's Range | 8.04 - 8.79 |
| 52-Week Range | 1.83 - 12.43 |
| Beta | -0.08 |
| Analysts | Strong Buy |
| Price Target | 12.50 (+47.93%) |
| Earnings Date | Feb 23, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $12.5, which is an increase of 47.93% from the latest price.
News
ImmunityBio Announces FDA Resubmission For Expanded Use Of Lead Drug
ImmunityBio Inc. (NASDAQ: IBRX) shares are trading lower on Monday.
ImmunityBio Announces Resubmission of Supplemental BLA to the FDA for ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC with Papillary Disease Following Agency Review of Additional Data
Following multiple meetings with the FDA, ImmunityBio submitted additional information requested by the Agency to support its supplemental BLA (sBLA) for papillary disease The FDA reviewed the additio...
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio, Inc. (IBRX) Q4 2025 Earnings Call Transcript
ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a busin...
ImmunityBio Investors Rally Behind Cancer Trial Milestone
ImmunityBio Inc. (NASDAQ: IBRX) shares are up during Thursday's premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Guér...
ImmunityBio Completes Enrollment in Pivotal Randomized Trial Evaluating ANKTIVA® Plus BCG Versus BCG Alone in BCG-Naïve Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced completion of enrollment in its Phase 2 clinical trial evaluating ANKTIVA® (...
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio Inc. (NASDAQ: IBRX) shares are down on Wednesday, cooling off from a huge up move as the company is reportedly experiencing significant revenue growth.
ImmunityBio's 471% Stock Rally Could Enter Next Round If Shorts Capitulate
Source: Benzinga
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation "Cancer 2035: A Roadmap for the Future" Summit
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (Nasdaq: IBRX), a commercial-stage biotechnology company pioneering next-generation immunotherapies, today announced that its Founder, Executive...
ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
ImmunityBio Inc. (NASDAQ: IBRX) shares are up on Monday following the company's announcement of significant revenue growth.
Undercovered Dozen: Agnico Eagle, Lumentum, ImmunityBio And More
The Undercovered Dozen series spotlights 12 less-covered stocks highlighted in recent Seeking Alpha articles. This week's edition covers articles published between Feb. 13 and Feb. 19, offering fresh ...
ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA® Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced full-year 2025 financial and operational highlights, including approxi...
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Biopharma and Cigalah, two of the largest and most ...
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
ImmunityBio Inc (NASDAQ: IBRX) stock is maintaining a confirmed Golden Cross, with the stock now trading roughly 170% above its 200-day moving average — a measurable signal of sustained long-term tren...
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced a partnership with Accord Healthcare to provide access to ANKTIVA® (no...
What's Behind The Jump In ImmunityBio Stock?
The authorization by the European Commission allows ImmunityBio to establish a substantial commercial footprint across four regulatory jurisdictions in less than two years from its initial FDA approva...
ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has granted conditional marketing authorization...
ImmunityBio: The Story Surrounding Anktiva So Far
ImmunityBio commands a premium valuation on the promise of Anktiva, a chemo-free immunotherapy platform showing early efficacy and manageable safety. IBRX's Anktiva is FDA-approved for BCG-unresponsiv...
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NYSE: IBRX), a commercial stage immunotherapy company developing next generation therapies that drive immunological memory and restore immune c...
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 clinical study evaluating a novel ch...
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company developing cytokine and cellular immunotherapies designed to restore immune competence,...
FDA Talks Set Path For Expanded Use For ImmunityBio's Anktiva In Bladder Cancer
ImmunityBio Inc. (NASDAQ: IBRX) on Tuesday said it plans to submit additional information to the U.S. Food and Drug Administration (FDA) within 30 days following a Type B end-of-phase meeting related ...
Top 3 Health Care Stocks You May Want To Dump In January
As of Jan. 20, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA re...